

## 2011 Care Wisconsin Prior Authorization Criteria

Therapeutic Category	Step Therapy Requirements
5-HT <sub>3</sub> Antagonist Antiemetics	Beneficiary must try ondansetron 4mg or 8mg for seven days as step one and fail therapy before being able to receive ondansetron 24mg, ondansetron ODTs, ondansetron solution, or any of the forms of granisetron for thirty days as step two and fail therapy before being able to get dolasetron or any of the forms of aprepitant as step three.
Angiotensin Receptor Antagonists	Beneficiary must try benazepril, benazepril/HCTZ, captopril, captopril/HCTZ, enalapril, enalapril/HCTZ, lisinopril, lisinopril/HCTZ, quinapril, or quinapril/HCTZ for thirty days as step one and fail therapy before being able to receive losartan or losartan/HCTZ for thirty days as step two and fail therapy before being able to receive candesartan, candesartan/HCTZ, valsartan, or valsartan/HCTZ as step three.
Antacid/Histamine (2) Blocking Agents	Beneficiary must try ranitidine for thirty days as step one and fail therapy before being able to receive famotidine as step two.
Anticholinergic Bronchodilators	Beneficiary must try ipratropium bromide or albuterol/ipratropium for thirty days as step one and fail therapy before being able to receive tiotropium bromide as step two.
Antipsychotic*	Beneficiary must try risperidone tablets or solution for thirty days as step one and fail therapy before receiving risperidone orally disintegrating tablets, risperidone consta injection, olanzapine tablets, quetiapine, olanzapine injection, aripiprazole ODT, olanzapine ODT, or ziprasidone for thirty days as step two and fail two ST2 therapies before being able to receive iloperidone, or paliperidone as step three. Any beneficiary currently taking risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, or paliperidone will not be subject to the step therapy restrictions.
Clostridium Difficile Oral Therapy	Beneficiary must try metronidazole for fourteen days as step one and fail therapy before receiving oral vancomycin as step two.
Desvenlafaxine*	Beneficiary must try venlafaxine for sixty days as step one and fail therapy before receiving desvenlafaxine as step two. Any beneficiary currently taking desvenlafaxine will not be subject to the step therapy restrictions.
Fibric Acid Dyslipidemics	Beneficiary must try gemfibrozil for sixty days as step one and fail therapy before receiving fenofibrate as step two.

\* PA applies to new starts only

## 2011 Care Wisconsin Prior Authorization Criteria

Therapeutic Category	Step Therapy Requirements
HMGCoA Inhibitors / Cholesterol Absorption Inhibitors	Beneficiary must try simvastatin 80mg for sixty days as step one and fail therapy before receiving atorvastatin for sixty days as step two and fail therapy before receiving ezetimibe or ezetimibe/simvastatin as step three.
Migraine Abortive Agents	Beneficiary must try sumatriptan tablets or injection for fourteen days as step one and fail therapy before being able to receive almotriptan tablets, zolmitriptan tablets, orally disintegrating tablets, or nasal spray as step two.
Non-Opioid Analgesics	Beneficiary must try oxaprozin, ibuprofen, or naproxen for thirty days as step one and fail therapy before receiving celecoxib as step two.
Opioid Analgesics	Beneficiary must try methadone or extended release morphine for thirty days as step one and fail therapy before receiving oxycodone SR for thirty days as step two and fail therapy before receiving fentanyl patches as step three.
Oral Antidiabetic Agents	Beneficiary must try metformin, glipizide, glyburide, or glimepiride for thirty days as step one and fail therapy before receiving glipizide/metformin, glyburide/metformin, miglitol, or repaglinide for thirty days as step two. Beneficiary must fail one therapeutic option from step two medications before receiving pioglitazone, rosiglitazone, rosiglitazone/glimepiride, rosiglitazone/metformin, acarbose, sitagliptin, sitagliptin/metformin, exenatide, or pramlintide as step three.
Proton Pump Inhibitors	Beneficiary must try omeprazole for thirty days as step one and fail therapy before receiving pantoprazole for thirty days as step two and fail therapy before receiving lansoprazole as step three.
Topical Analgesics	Beneficiary must try topical lidocaine ointment or gel for thirty days as step one and fail therapy before receiving Lidoderm patches or lidocaine/prilocaine cream as step two.
Urinary Antispasmodics	Beneficiary must try oxybutynin or oxybutynin ER for thirty days as step one and fail therapy before receiving tolterodine for thirty days as step two and fail two therapeutic options before receiving tolterodine ER, darifenacin, solifenacin, trospium, or Oxytrol as step three.
Xolair	Beneficiary must try zafirlukast or montelukast for thirty days as step one and fail therapy before receiving omalizumab as step two.
Tramadol	Beneficiary must try tramadol for thirty days as step one and fail therapy before receiving tramadol ER.

\* PA applies to new starts only

## 2011 Care Wisconsin Prior Authorization Criteria

Therapeutic Category	Step Therapy Requirements
Osteoporosis	Beneficiary must try alendronate or etidronate for 6 months as step one and fail therapy before receiving ibandronate, calcitonin, or risedronate for 6 months as step two and fail therapy before receiving teriparatide (Forteo) or Zometa (zoledronic acid) as step three.
Sympathomimetic Bronchodilators	Beneficiary must first try Ventolin HFA for 30 days as step one and fail before receiving Proair as step two.
Tricyclics	Beneficiary must try desipramine or clomipramine as step one and fail therapy before receiving trimipramine as step two.
Pulmonary Antihypertensives	Beneficiary must try sildenafil or tadalafil as step one and fail therapy before receiving ambrisentan as step two.

\* PA applies to new starts only